32 Participants Needed

Ketogenic Diet for Pancreatic Cancer

Recruiting at 6 trial locations
BP
KG
KN
KS
Overseen ByKhara Stemley
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Translational Drug Development
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This study will evaluate the effects of the ketogenic diet in patients with metastatic pancreatic cancer while receiving chemotherapy.

Research Team

SN

Steve Norton, MBA PhD

Principal Investigator

Translational Drug Development

Eligibility Criteria

This trial is for adults with metastatic pancreatic ductal adenocarcinoma who haven't been treated for their advanced disease. They must be able to perform daily activities (KPS ≥ 70%), have a life expectancy of at least 12 weeks, and measurable tumor lesions. Participants need a smartphone or computer, acceptable blood counts and organ function, and agree to use contraception if necessary. Excluded are those with severe malnutrition, certain heart conditions, recent major surgery, uncontrolled illnesses or infections.

Inclusion Criteria

Your tumors can be measured using specific guidelines called RECIST 1.1.
I do not have severe numbness or pain in my hands or feet.
You are expected to live for at least 12 more weeks.
See 8 more

Exclusion Criteria

I do not have any severe illnesses like serious heart conditions.
I have had diabetic ketoacidosis in the past.
I do not have any ongoing serious infections needing treatment.
See 11 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either a ketogenic or non-ketogenic diet along with triplet chemotherapy (nab-paclitaxel, cisplatin, gemcitabine) administered intravenously on Days 1 and 8 every 21 days

36 months
Visits every 21 days for chemotherapy administration

Follow-up

Participants are monitored for progression-free survival, changes in serum metabolites, quality of life, and other secondary outcomes

36 months

Treatment Details

Interventions

  • Ketogenic Diet
Trial Overview The study tests the ketogenic diet's effects on patients with advanced pancreatic cancer while they undergo chemotherapy. The goal is to see how this high-fat, low-carbohydrate diet might influence cancer treatment outcomes.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Ketogenic (KD) + TripletExperimental Treatment1 Intervention
Ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
Group II: Non-ketogenic + TripletActive Control1 Intervention
Non-ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Translational Drug Development

Lead Sponsor

Trials
19
Recruited
1,000+

Translational Genomics Research Institute

Collaborator

Trials
36
Recruited
107,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security